Ebrantil

Ebrantil – anti-adrenergic medicine from group _{α1-адреноблокаторов}.

On pharmacological group Omsulozin, Zokson, Alfazuzozin, Butiroksan, Dalfaz, Giperprost, Yokhimbina a hydrochloride, Cardura, Kornam, Nitsergolin, Omnik, Pyrroxanum, Omsulozin, Prazozin, Proroksan, Profloksin, Polpressin, Nilogrin, Kamiren, Ditamin, Artezin, Terazozin, Urokard, Fokusin, Setegis, Redergin, Urorek, Tamsulozin, Revokarin treat Ebrantil's analogs.

Drug Ebrantil has no structural analogs on the main operating component.

Structure and form of release

According to the instruction Ebrantil is issued in the form of solution for intravenous injections (in ampoules on 5, 10 ml), and also in the form of capsules (30, 60 and 90 mg).

1 ml of Ebrantil contains 5 mg of an urapidil – the main operating medicine component. Auxiliary components: propylene glycol, a hydrosodium phosphate dihydrate, a dihydrosodium phosphate dihydrate, water for injections.

One capsule of a medicine contains 30, 60 or 90 mg of an urapidil respectively. Additional components: methylmethacrylate copolymer (type B), talc, diethyl phthalate, gipromelloza, fumaric acid, ethyl cellulose, gipromelloza phthalate, stearic acid, sugar spherical.

Pharmacological action of Ebrantil

Ebrantil, blocking postsynaptic _{α1-адренорецепторы}, reduces peripheric resistance. Besides, Ebrantil has poorly expressed beta and adrenoceptor blocking effect, participates in regulation of the mechanism of maintenance of a tone of vessels. Cordial emission and ChSS at Ebrantil's introduction do not change.

Drug it is balanced the ABP reduces (diastolic and systolic), promotes reduction of peripheric resistance, without causing at the same time reflex tachycardia.

Action of an urapidil promotes increase in reduced minute volume of heart, decrease in load of a cardiac muscle and increase in efficiency of cordial reductions.

In TsNS active ingredient of drug influences activity of a vasomotor center, interfering with reflex decrease (or to increase) a tone of a sympathetic part of the nervous system.

Urapidil in no way does not influence exchange of uric acid and indicators of exchange of carbohydrates, does not cause a liquid delay in an organism.

Ebrantil easily gets through placental and hematoencephalic barriers. The maximum concentration of an urapidil in a blood plasma is reached in four-six hours after Ebrantil's use. The most part of an urapidil is metabolized in a liver. Urapidil and his metabolites are removed by kidneys (55-70%) and through intestines.

Indications to use

According to the instruction Ebrantil is applied at hypertensive crisis, refractory arterial hypertension, and also to the managed decrease in the increased arterial pressure after and/or during surgical interventions.

The instruction to use

According to the instruction Ebrantil enter intravenously by long infusion or a jet way. Medicine capsules Ebrantil should be accepted twice a day, in the morning and in the evening, during meal, washing down with a small amount of liquid. At refractory hypertensia, arterial hypertension in a severe form, hypertensive crisis enter 10-50 mg of Ebrantil intravenously under control of arterial pressure. The lowering of arterial pressure has to occur in five minutes after an injection. Depending on medical effect perhaps repeated introduction of a medicine.

Use the perfused pump to continuous or intravenous drop injections. A maintenance dose – about 9 mg/h, i.e. 250 mg of a medicine part in 0,5 l of solution for injections. The most admissible concentration – 4 mg of Ebrantil on 1 ml of solution for injections (5% or 10% solution of glucose (dextrose) or normal saline solution). Speed of drop intravenous administration of drug depends on indicators of arterial pressure of the patient.

When using the perfused pump of 100 mg of Ebrantil enter into the syringe and part to 50 ml 5% or 10% with solution of glucose (dextrose) or normal saline solution.

At increase in the ABP after and/or during surgical interventions for the purpose of his controlled decrease administer the drug Ebrantil intravenously in a dose of 25 mg. Decrease in indicators of arterial pressure has to happen within two minutes after introduction. Further stabilization of the ABP by means of infusion is carried out.

If stabilization of indicators of pressure does not occur a long time, then carry out slow intravenous administration of a medicine Ebrantil in a dose of 50 mg.

If earlier other hypotensive drugs were used, then Ebrantil it is possible to enter not earlier than the beginning of action of the entered medicine.

Apply 30 mg of a medicine to a gradual lowering of arterial pressure twice a day.

The recommended Ebrantil's dose for a bystry lowering of arterial pressure – on 60 mg twice a day. Total quantity of an urapidil has to make from 60 to 180 mg a day.

Contraindications to Ebrantil's use

• aortal stenosis;
• children's age up to 18 years;
• pregnancy;
• lactation period;
• hypersensitivity to Ebrantil;
• the channel opened botall.

With care it is necessary to apply Ebrantil at advanced age, at a hypovolemia, and also at a renal failure and/or a liver.

Side effect

At prolonged use of Ebrantil there can be following collateral symptoms: vomiting, nausea, arrhythmia, short wind, headache, nephropathy, dizziness. Sometimes there is a skin itch, bradycardia or tachycardia, heartbeat, feeling of concern, thrombocytopenia, a nephrotic syndrome.

Overdose by Ebrantil

Symptoms of overdose by Ebrantil: orthostatic hypotension, dizziness, collapse, reduction in the rate of reactions, fatigue.

Therapy: reduction of the progressing pressure decrease of blood at the expense of a raising up the lower extremities, substitution of volume of the circulating blood; in the absence of effect – slow intravenous administration of vasoconstrictors. In rare instances apply intravenous administration of catecholamines.

Storage conditions

Storage temperature – no more than 30 °C.

Period of storage – 2 years.